Alvotech (ALVO) Projected to Post Quarterly Earnings on Wednesday

Alvotech (NASDAQ:ALVO) is anticipated to release its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Alvotech to post earnings of ($0.07) per share and revenue of $112.3860 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Alvotech (NASDAQ:ALVO) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.50). Alvotech had a net margin of 4.74% and a negative return on equity of 11.92%. The business had revenue of $173.20 million for the quarter, compared to analysts’ expectations of $162.20 million. On average, analysts expect Alvotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Alvotech Price Performance

Shares of NASDAQ ALVO opened at $3.52 on Tuesday. Alvotech has a 1 year low of $3.03 and a 1 year high of $11.85. The stock has a market cap of $1.06 billion, a P/E ratio of 35.20 and a beta of 0.21. The firm has a 50-day moving average of $3.64 and a 200 day moving average of $4.87.

Analyst Ratings Changes

A number of brokerages recently issued reports on ALVO. Weiss Ratings reissued a “sell (e+)” rating on shares of Alvotech in a research report on Monday, April 20th. UBS Group lowered their price target on shares of Alvotech from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, March 24th. Barclays lowered their price target on shares of Alvotech from $5.00 to $4.00 and set an “underweight” rating for the company in a research report on Tuesday, March 24th. Wall Street Zen raised shares of Alvotech from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Finally, Zacks Research raised shares of Alvotech from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 19th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alvotech currently has an average rating of “Hold” and an average price target of $7.60.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ALVO. Goldman Sachs Group Inc. raised its holdings in Alvotech by 40.9% in the first quarter. Goldman Sachs Group Inc. now owns 36,444 shares of the company’s stock worth $352,000 after buying an additional 10,573 shares during the last quarter. Geode Capital Management LLC raised its holdings in Alvotech by 0.7% in the second quarter. Geode Capital Management LLC now owns 230,291 shares of the company’s stock worth $2,100,000 after buying an additional 1,574 shares during the last quarter. Invesco Ltd. raised its holdings in Alvotech by 37.3% in the second quarter. Invesco Ltd. now owns 32,398 shares of the company’s stock worth $295,000 after buying an additional 8,794 shares during the last quarter. Bank of America Corp DE raised its holdings in Alvotech by 218.0% in the second quarter. Bank of America Corp DE now owns 16,623 shares of the company’s stock worth $152,000 after buying an additional 11,395 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC purchased a new position in Alvotech in the second quarter worth about $1,782,000.

Alvotech Company Profile

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).